<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964730</url>
  </required_header>
  <id_info>
    <org_study_id>TAL-TQT-101</org_study_id>
    <secondary_id>R09-0539</secondary_id>
    <nct_id>NCT00964730</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm</brief_title>
  <official_title>A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether multiple doses of Talampanel increase the QT
      interval when compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effects of Talampanel on cardiac repolarization after multiple therapeutic doses administered over 10 days</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the PK profile of talampanel and its metabolite -Assess the PK/PD relationship of the time course of QT/QTc interval prolongation-Assess the safety and tolerability of multiple doses of talampanel in healthy volunteers</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Talampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>titrated to 50mg three times a day over 9 days and a single dose administered on Day 10</description>
    <arm_group_label>Talampanel</arm_group_label>
    <other_name>TV-7600, GYKI 53773</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered three times a day over 9 days and a single dose administered on Day 10</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged 18 to 50 years of age inclusive.

          -  Body mass index: Between 18 and 30 kg/m2 and weight of at least 50 kg.

          -  Female volunteers must have either a negative pregnancy test and be willing to use
             birth control, be post-menopausal evidenced by lab test, or be surgically sterile.

          -  Volunteers must be able to understand the requirements of the study and must be
             willing to comply with the requirements of the study and provide their written
             informed consents to participate in the study prior to the conduct of study
             procedures.

        Exclusion Criteria:

          -  Male and female volunteers with a resting QT interval of &lt; 320 msec or &gt; 450 msec
             (males) or &gt; 470 msec (females

          -  Volunteers with ECG abnormalities that may interfere with the accurate assessment of
             the QT interval

          -  Volunteers with known cardiovascular disorders, including coronary artery disease,
             valvular heart disease, cardiomyopathies, or ECG abnormalities suggestive of prior
             myocardial infarction, chamber enlargement or hypertrophy.

          -  Volunteers with known clinically significant arrhythmias or rhythm disturbances
             observed on ECG

          -  Volunteers who have a history of, or risk factors for, Torsades de Pointes (e.g. heart
             failure, abnormal serum electrolytes), including a history of family history of
             arrhythmia, sudden death, long QT syndrome, Brugada complex, or personal history of
             syncope.

          -  Volunteers who have a heart rate outside 40-90 beats per minute

          -  Volunteers who have a blood pressure outside 90-140 mmHg systolic or 45-90 mmHg
             diastolic

          -  Volunteers with history of uncontrolled hypertension, impaired glucose tolerance,
             diabetes mellitus, kidney disease, edema, stroke or neurological disorder,
             rheumatological disorder, lung disease, heart disease, liver disease, or a history of
             any illness that pose additional risk to the volunteer

          -  Volunteers with a history of psychiatric disorders, including bipolar disorder,
             psychosis, previous episode(s) of major depression, history of suicidality or suicidal
             ideation.

          -  Volunteers who have history of surgeries or conditions that affect the way drugs are
             absorbed or distributed in the body such as intestinal surgery, stomach surgery.

          -  Volunteers with impaired liver function and elevated liver enzymes

          -  Volunteers with major trauma or surgery in the past 2 months, acute infection within 2
             weeks, cancer within the last 5 years (excluding non-melanoma skin cancers), History
             of tuberculosis, abnormal lab tests

          -  Female volunteers who are lactating or intend to become pregnant during the study
             period.

          -  Volunteers with a known allergy or sensitivity to moxifloxacin or its derivatives,
             benzodiazepines, talampanel or its derivatives, or any contraindications to
             moxifloxacin, benzodiazepines, or talampanel.

          -  Volunteers with significant food or drug allergies

          -  Volunteers that have used an investigational drug (new chemical entity) 3 months prior
             to the start of the study,.who have consumed any medications (including
             over-the-counter medications, prescription medications, investigational drugs,
             vitamins, or herbal remedies) within 30 days prior to check-in (with the exception of
             hormonal contraceptives [females only] and occasional use of acetaminophen and
             ibuprofens, who have consumed amiodarone and chloroquine within 4 months prior to
             screening, who have consumed excessive amounts of alcohol or are unwilling to comply
             with the restricted use of alcohol during the study, who have consumed excessive
             amounts of coffee, tea, coke, or other caffeinated beverages within 2 weeks prior to
             check-in, who have consumed quinine (tonic water) within 7 days prior to study start,
             who have consumed grapefruit, grapefruit juice, or Seville orange juice within the 7
             days prior to study start, who smoke, have smoked in the last 3 months, or are
             planning to start smoking during the study, tobacco users, subjects currently using
             nicotine products, or subjects with a positive urine cotinine test at study start

          -  Volunteers who are currently regular users (including recreational use) of any illicit
             drugs or who have a history of drug (including alcohol) abuse within 1 year of study
             start.

          -  Volunteers with positive urine test for drugs of abuse at screening or check-in.

          -  Volunteers who have donated or received any blood, plasma, or platelet transfusions in
             the 3 months prior to study start, or who have made donations on more than two
             occasions within the 12 months preceding the first dose administration, or who have
             planned donations during the study or during the 3 months following the study.

          -  Volunteers with a positive screening test for Hepatitis B, Hepatitis C or HIV

          -  Volunteers not willing to refrain from changing level of activity during the study and
             from jogging and strenuous exercise of all types while at the research unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig R Sprenger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research - Fargo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research - Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>April 6, 2010</last_update_submitted>
  <last_update_submitted_qc>April 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, M.D., Ph.D. VP</name_title>
    <organization>Teva Neuroscience, Inc</organization>
  </responsible_party>
  <keyword>Thorough QT Study</keyword>
  <keyword>Talampanel</keyword>
  <keyword>Cardiac Repolarizatiom</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

